4598 · Delta-Fly Pharma, Inc. · Financials
Market Cap
881.94M JPY
Shares
14.22M
Volume · Nov 13
311.2K
Avg daily vol (3M)
1.4M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.
Net Income
-1.63B
+5.5%
FY2026
Operating Cash Flow
-1.56B
+15.1%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| JPY | -1.61B | -1.71B | -1.4B | -1.32B | -961.46M |
| JPY | -1.62B | -1.72B | -1.43B | -1.33B | -964.06M |
| JPY | 2.5M | 2.5M | 2.5M | 3.03M | 3.24M |
| JPY | -1.63B | -1.72B | -1.43B | -1.33B | -967.3M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.